Advertising Disclosure: This site contains affiliate links. We may earn a commission if you purchase through our links, at no extra cost to you. Learn more
Ozempic, Wegovy, Mounjaro, Zepbound — these brand names get used almost interchangeably in casual conversation, but they're not all the same drug, and understanding how they actually work helps cut through a lot of the noise.
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally releases after you eat. It tells your pancreas to release insulin, tells your liver to stop overproducing sugar, and signals your brain that you're full. GLP-1 receptor agonist drugs — semaglutide and tirzepatide are the two most common — are engineered to mimic this hormone but last far longer in the body, which is why they're taken as a once-weekly injection instead of needing to be produced fresh after every meal.
GLP-1 receptors in the hypothalamus and brainstem — the brain regions that regulate hunger — respond to the drug by signaling fullness earlier and more strongly than the body's natural GLP-1 would. This is the primary driver of reduced calorie intake, according to clinical and non-clinical research on semaglutide.
Food stays in the stomach longer before moving to the small intestine, extending the physical sensation of fullness after a meal and further reducing the drive to eat again soon after.
The drug enhances insulin secretion specifically when blood sugar is elevated (not constantly, which reduces the risk of dangerously low blood sugar) and lowers glucagon, the hormone that raises blood sugar — the mechanism behind its original approval for type 2 diabetes.
In the STEP 1 clinical trial, participants using semaglutide 2.4mg weekly (the Wegovy dose) lost an average of 17.3% of body weight over 68 weeks, compared to 2.0% in the placebo group receiving lifestyle intervention alone. That's a substantial, clinically meaningful effect — far beyond what most non-prescription approaches achieve.
This is the part that gets far less attention than the before-and-after photos. In the same STEP 1 trial's extension study, participants regained roughly two-thirds of their lost weight within one year of stopping the medication, with cardiometabolic markers shifting back as well. A broader meta-regression across multiple studies found regain trajectories plateauing around 75% of the weight originally lost. These medications were designed as long-term, ongoing treatments — not a course you complete and finish.
Wegovy and Zepbound are FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Ozempic and Mounjaro remain approved specifically for type 2 diabetes, meaning their use for weight loss alone is off-label — a distinction that matters for insurance coverage, which is a major reason many people who start these medications don't stay on them long-term.
Hormovance is formulated with Berberine, Green Tea Extract, and other studied ingredients that support many of the same underlying targets — blood sugar, appetite, and metabolism — without an injection or prescription.
See the Full Ingredient List →For a direct comparison of how these two approaches differ, see our GLP-1 vs. natural supplements breakdown.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that require a doctor's evaluation and ongoing supervision. Do not start, stop, or adjust any medication without consulting a qualified healthcare provider.